This site uses third party services that need your consent. Learn more

Skip to content

Condition update published on

AVROBIO ends its gene therapy trial for Fabry disease


We are sad to announce that the pharmaceutical company AVROBIO has made the difficult decision to deprioritize its gene therapy trial for Fabry disease. It is another in a line of disappointments for

new therapies in the last year and it is hard on the Fabry community that we support.

If you need to speak to a member of the Support and Advocacy Team, please call 0345 389 9901.

You can read the full press release from AVROBIO here.

More condition posts